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Reduced levels of frataxin, an essential mitochondrial protein involved in the regulation
of iron-sulfur cluster biogenesis, are responsible for the recessive neurodegenerative
Friedreich Ataxia (FRDA). Expansion of a GAA triplet in the first intron of the FRDA
is essential for disease development which causes partial silencing of frataxin. In
the vast majority of cases, patients are homozygotes for the expansion, but a small
number of FRDA patients are heterozygotes for expansion and point mutations in
the frataxin coding frame. In this study, we analyze the effects of a point mutation
G137V. The patient P94–2, with a history of alcohol and drug abuse, showed a FRDA
onset at the border between the classic and late onset phenotype. We applied a
combination of biophysical and biochemical methods to characterize its effects on
the structure, folding and activity of frataxin. Our study reveals no impairment of
the structure or activity of the protein but a reduced folding stability. We suggest
that the mutation causes misfolding of the native chain with consequent reduction
of the protein concentration in the patient and discuss the possible mechanism of
disease.
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INTRODUCTION
Friedreich ataxia (FRDA, OMIM 229300) is the most common form of recessively inherited
ataxia, a neurodegenerative disease associated to loss of voluntary movement (Pastore and
Puccio, 2013). Although the disease incidence is ca. 1 in 50,000 individuals, heterozygotic
carriers are as frequent as 1 in 250 individuals. Primarily, FRDA is caused by the presence
of a (GAA)n expansion within the first intron of the FXN gene, which encodes the frataxin
protein. The severity of the disease is correlated with the number of repeats (Pastore and
Puccio, 2013), which is lower than 30 in normal alleles and between 66 and 1700 in FRDA
patients (Clark et al., 2004). Repeat expansion leads to epigenetic changes which result in
partial gene silencing by blocking the transition from initiation to a productive elongation
of frataxin transcription (Kim et al., 2011). Typically, FRDA patients have frataxin levels
in peripheral tissues that range from 2–30% as compared to control levels (Deutsch et al.,
2010; Nachbauer et al., 2011; Saccà et al., 2011, 2013). These levels correlate directly with
age of onset and inversely with the number of GAA repeats. Carriers who do not develop
symptoms of FRDA have typically frataxin levels from 30–80% of control levels. However,
a certain variability is observed which makes it difficult to correlate precisely the frataxin
levels with the severity of phenotype.
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The vast majority of FRDA patients are homozygous for
the expansion. A small fraction of patients (4%), however,
are heterozygous for triplets expansion on one allele and
a point mutation on the other (Cossée et al., 1999). To
date at least 20 point mutations have been reported (Pook
et al., 2000). These patients can present either the classical
FRDA phenotype or an atypical clinical presentation (Cossée
et al., 1999). The genotype-phenotype correlation of such
patients is usually less predictable depending on the nature
and position of the mutation (Pook et al., 2000). Contrary
to GAA expansion that alters protein levels, these mutations
often directly affect the function of the expressed protein.
The phenotype of these patients is nevertheless most of
the time indistinguishable from homozygous individuals,
except in the case of a few missense mutations causing
atypical or milder clinical presentations (Cossée et al., 1999;
Gellera et al., 2007).
A close study of these point mutations, by looking at their
effects on the fold, stability and activity of frataxin is interesting
to gain new insights into the role of frataxin in the onset of the
disease and contribute to a better understanding of the protein
function.
Frataxin is ubiquitously expressed at low levels. Higher
concentrations are found in the heart, spinal cord and dorsal
root ganglia, all tissues that are heavily dependent on oxidative
respiration (Campuzano et al., 1996). Frataxin is an acidic protein
with iron-binding properties and highly conserved in most
organisms from bacteria to mammals (Adinolfi et al., 2002).
It is a nuclearly-encoded mitochondrial protein (Campuzano
et al., 1997). The mature human protein contains 130 amino
acids (Condò et al., 2007) 14kDa distributed in two structurally
distinct regions, with a C-terminal globular domain preceded
by a flexible and unstructured N-terminus which is part of the
mitochondrial import signal (Musco et al., 2000; Prischi et al.,
2010). Frataxin is an essential component of the iron-sulfur
cluster biogenesis (Mühlenhoff et al., 2003; Adinolfi et al., 2009)
in which it acts by interacting with the two central components
of this machinery, the desulphurase Nfs1/IscS (human and
bacterial forms, respectively) and the scaffold protein Isu/IscU
(human and bacterial forms, respectively; Prischi et al., 2010).
Independent evidence suggests that frataxin acts as a sensor
protein, tuning the quantity of clusters formed in order to
match the concentration of the apo-acceptors (Adinolfi et al.,
2009).
In this study, we examined a point G137V mutation,
found in a FRDA patient. We explored the structure-function
relationship and carried out a detailed investigation of the
possible consequences of this mutation on the frataxin fold,
stability and function using complementary biochemical and
biophysical structural techniques in vitro which include Circular
Dichroism (CD), absorbance and Nuclear Magnetic Resonance
(NMR) spectroscopies and enzymatic assays. Structural studies
revealed no appreciable consequences on the fold and activity but
an appreciable loss of stability. We suggest that reduced stability
might affect the efficiency of folding of the native chain resulting
in reduced levels of the protein, as also observed for other FRDA
clinical mutations.
MATERIALS AND METHODS
Genetic Test
The genetic test was approved by the Ethical Commettee
of Azienda Ospedaliera Sant’Andrea of Rome ‘‘La Sapienza’’
and conducted according to the principles expressed in the
Declaration of Helsinki. All participants signed written informed
consent.
Mutation Analysis
The test for the specific disease mutation (expansion of GAA
repeats in FXN gene LRG_339t1 intron 1) was performed in
double by PCR amplification of GAA repeats (Filla et al., 1996).
The result was confirmed by TP PCR on capillary electrophoresis
(Ciotti et al., 2004). DNA sequencing for mutation screening
of FXN gene was performed using primer pairs according to a
previously described protocol (Campuzano et al., 1996).
Expression and Purification of
Recombinant Proteins in E. Coli
The QuikChange method (Stratagene) was used to introduce
the point mutation into a pET-24 plasmid containing the
human frataxin gene (residues ∆91–210, corresponding to the
mature form of human frataxin hereon called Hfra(91–210)).
The mutation site was confirmed by DNA sequencing. All
recombinant proteins were expressed in E. coli and purified
according to previously published protocols (Musco et al., 2000;
Prischi et al., 2010). In short, the plasmid containing the variant
as a fusion protein with His6 and GST (glutathione S-transferase)
tags and a cleavage site for Tobacco Etch Virus (TEC) was
transformed into the E. coli strain BL21(DE3)pLys (Novagen).
The cells were grown in Luria–Bertani (LB) medium with
kanamycin. Protein expression was induced with IPTG. The cells
were harvested and lysed by sonication. After centrifugation,
the supernatant was loaded on Ni-NTA agarose beads (batch)
and the protein eluted with 300 mM imidazole. The tag was
cleaved with the TEV protease overnight. A second step of
Ni-NTA agarose purification allowed collecting the protein
eluted separately from the tag. Final purification was performed
by gel filtration. The procedure followed for the purification
of Nfs1 and Isu was the same except for the further addition
of biotine-thiamine (0.001–0.005 mg/mL) and 8.3 mM zinc in
the growing medium of Nfs1 and Isu respectively. 0.5 mM
TCEP was preferred over DTT in the purification protocol
of Isu.
Circular Dichroism Measurements
Far-UV CD spectra were recorded with a Jasco J-815
spectropolarimeter using a cell holder thermostated by a
CDF-426S Peltier unit. All CD measurements were carried out
in the buffer used for gel filtration (20 mM Tris-HCl at pH 8,
150 mM NaCl and 2 mM DTT) with 10 µM protein, using fused
silica cuvettes with 1 mm pathlength (Hellma Materials GmbH
& Co, Jena, Germany). The spectra were typically recorded with
0.1 nm resolution and baseline corrected by subtraction of the
appropriate buffer spectrum. Secondary structure content was
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estimated using methods described by Sreerama and Woody
(2000). Thermal unfolding curves were obtained by monitoring
the ellipticity at 222 nm using 2 mm path length cuvettes and
a heating rate of 1◦C/min over the temperature range 0–80◦C.
The transition mid-point temperature was obtained by fitting
to the modified Gibbs-Helmholtz equation using in-house
software as described elsewhere (Martin and Schilstra, 2008).
Each experiment was repeated atleast three times.
Nuclear Magnetic Resonance
One-dimensional 1H NMR spectra were recorded at 298 K
on Varian INOVA spectrometer operating at 600 MHz 1H
frequency (14.1 Tesla magnetic field). The proteins (100 µM)
were dissolved in the same buffer as for CD, with a further
addition of 10% deuterated water.
In Vitro Iron-Sulfur Cluster Formation
On IscU
Enzyme kinetics experiments were performed in a total volume
of 800 µL. The reaction mixtures were prepared under anerobic
conditions using a Controlled Atmosphere Chamber (Belle
technology). The scaffold protein IscU (50 µM) was pre-
incubated with Nfs1 (1 µM), frataxin or its mutant (5 µM),
3 mM DTT and 25 µM iron in buffer (20 mM Tris-HCl at
pH 8, 150 mM NaCl) for 30 min. The reaction was initiated
by addition of 250 µM L-cysteine. Kinetic curves of the iron-
sulfur cluster formation in vitro were obtained by following the
variation in the CD at 435 nm during the time using a Jasco J-815
CD spectropolarimeter. Each experiment was repeated atleast
three times.
Frataxin Levels
The frataxin levels in the proband, his father and mother
were probed by Western blot. A healthy individual was
used as a control. The experiment was carried out in
triplicates starting from two independent blood samples
taken approximately one month apart. Fresh peripheral
blood mononuclear cells (PBMC) were isolated from blood
by density gradient centrifugation with Lympholyte Cell
Separation Media (Cederlane) in Sepmate tubes (StemCell
Technologies) following the manufacturer’s protocol. Total
cell extracts from PBMC were prepared in ice-cold modified
RIPA buffer (10 mM sodium phosphate pH 7.2, 150 mM
NaCl, 1% Na deoxycholate, 0.1% SDS, 1% Nonidet P-40,
2 mM EDTA) supplemented with the Complete protease
inhibitor cocktail (Roche Diagnostics). The protein extract
(100 µg) was separated by 12% SDS–PAGE, blotted onto
a nitrocellulose membrane (Trans-Blot Turbo Transfer
System, Bio-Rad Laboratories) monitored by ECL detection
(GE Healthcare Life Sciences) with mAb anti-frataxin
(18A5DB1 from AbCam) and pAb anti-actinC11 antibodies
(sc1615 from Santa Cruz) and imaged with a ChemiDoc
XRS system (Bio-Rad Laboratories). Densitometric analysis
was performed using the ImageLab 4.1 Software (Bio-Rad
Laboratories).
RESULTS
Patient’s Description and Mutation
Analysis
The FRDA patient, male, was seen at S. Andrea Hospital in
Rome (Italy) when he was 29 years old. The patient had a
history of alcohol and psychoactive drug abuse since age 17.
At the age of 25, he began with gait imbalance, frequent
falls and feet paresthesias. Admitted to hospital when 26 years
old, the proband presented mild scanning dysarthria, gait and
trunk ataxia, dysdiadocokynesia, absent tendon reflexes at upper
and lower limbs, impaired position and vibratory sense in
lower limbs. Sensory Evoked Potential (SEP) showed a non
recordable cortical response at right and a very long latency
at left in lower limbs, and cortical response of low amplitude
and long latency bilaterally at upper limbs. Brainstem Auditory
Evoked Response (BAER) showed long latency wave III and
V bilaterally. He presented signs of ventricular hypertrophy
at echocardiography and sensory axonal polyneuropathy at
Electromyography (EMG). Fundus oculi, cognitive performance,
blood glucose and brain MRI were normal. The onset at 25 years
of age places this patient at the boundary between a classical and
a late onset phenotype (Metz et al., 2013). Alcohol and drug abuse
did not thus seem to have a strong impact in determining the age
at onset.
Genetic analysis showed that the patient carries a
GAA expansion (250 repeats) and a heterozygous G > T
mutation in the exon 4 of the FXN gene at nucleotide 410
(NM_000144.4:c.410G > T) resulting in a substitution of a highly
evolutionary conserved glycine at codon 137 (p.Gly137Val) into
a valine. Of the two parents, the father is heterozygous for GAA
triplet expansion (250 repeats). The mother is heterozygous for
the mutation, the other allele being non-expanded.
Mapping the Mutation on the Frataxin
Structure
To rationalize the role of the mutation, we mapped it onto the
frataxin structure and compared its position with other clinically
important missense mutations. Interestingly, G137 maps in the
evolutionary conserved C-terminal domain (residues 92–210)
as all the other missense mutations, strongly suggesting that
this region is the functionally most important region. The
C-terminal domain forms a compact globular fold with an alpha-
beta structure (Musco et al., 2000). Two helices (95–113 and
182–194) pack against an anti-parallel beta-sheet formed by
seven consecutive strands. The knownmutations cluster into two
families which have interesting commonalities (Figures 1A,B).
Residues Leu106, Ile154, Leu156, Trp173, Leu182 and His183
are all part of the hydrophobic core and nearly all pack against
each other, suggesting that their mutations cause complementary
destabilization of the fold. The second family contains exposed
residues. Trp155 and Arg165 pack against each other as many
tryptophan-arginine pairs do because of the energetic gain
of delocalizing pi electrons (Burley and Petsko, 1986). The
remaining mutations affect Asp122, Gly130 and Gly137. Gly130
is at the beginning of the β1β2 turn and is a residue in the
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 November 2015 | Volume 8 | Article 66
Faggianelli et al. A New G137V Mutation in the FXN Gene
FIGURE 1 | Mapping the G137V mutation on the frataxin structure.
(A) Ribbon diagram of the human frataxin C-terminal domain (residues
92–210, pdb code 1LY7). The side chains of clinically important mutations are
shown explicitly (glycines are identified by spheres). Buried residues which
participate to the hydrophobic core are shown in yellow, exposed residues are
shown in magenta. (B) Zoom on the loop hosting G137 in silico mutated to
valine with the surrounding residues N122 and L135, highlighting a possible
steric hindrance caused by the mutation. (C) Ramachandran plot of the
frataxin where glycines 130 and 137 are explicitly marked.
disallowed region of the Ramachandran plot having both positive
phi and psi angles (Figure 1C). Gly137 is located at the end
of the strand β2, just before Gly138 which has a role similar
to Gly130 but in the β2β3 turn. As this residue, Gly138 has
also positive phi values. Glycine and valine are both non-polar
residues but valine has a bulkier side chain, which could cause
steric hindrance with other neighboring residues (e.g., Asp122
and Lys135). Mutation of glycines into any other amino acid
will also have an important influence on the turn conformation
because of the unique possibility of glycines of adopting positive
phi values.
Gly137 is not evolutionary conserved as the rest of the turn
but present in several eukaryotes. It is replaced by a glutamate in
bacterial frataxins (e.g., Glu44 in E. coli CyaY) and corresponds
to a proline (Pro63) in S. cerevisiae frataxin Yfh1 (Figure 2).
The G137V Mutation does not Affect
Structure but Strongly Destabilizes the
Fold
We then probed in vitro the effect of the mutation on the
structure of the frataxin variant by producing the human protein
by overexpression in bacteria. We used a fragment 90–210 of
the protein, rather than the full-length protein, because this
already extensively characterized variant spans the evolutionary
conserved C-terminal domain which is the only region of the
protein with a tertiary fold and the functionally important part
of the protein (Musco et al., 2000).
We could observe an effect of destabilization of the
fold already at the level of overexpression. When expressed
in E. coli, the wild-type protein mostly expresses as a
soluble protein. At variance, the G137V mutant is partly
expressed in inclusion bodies so that lower amounts of the
protein are obtained in the soluble fraction used for the
purification (Figure 3). A similar behavior was previously
observed for other missense mutants (Correia et al., 2008).
Although indirect because obtained in a heterologous host, this
behavior suggests a lower folding efficiency (Winkelmann et al.,
2010).
We recorded a one-dimensional 1H NMR spectrum of
the purified protein. A wide dispersion of the resonances
(Figure 4A), especially in the regions of methyl and HN signals
(i.e., between 1 and -1 ppm and between 12–7 ppm respectively)
is typical of stably folded proteins and proves that the G137V
mutant retains its tertiary structure. The spectrum is similar to
that of the wild-type protein. Consequently the mutation seems
to have no effect on the global fold.
These data were confirmed by CD. The far-UV CD spectrum
of the G137V mutant has features very similar to those of
the wild-type protein, presenting two minima at ca. 208 and
222 nm that are typical of proteins with an appreciable helical
structure content (Figure 4B). However, a thermal denaturation
scanning followed by CD gave a behavior markedly different
from that of the wild-type (Adinolfi et al., 2002; Correia
et al., 2006; Figure 4C). Thermal unfolding is reversible for
both proteins but the melting temperature of the mutant is
appreciably lower (46◦C and 66◦C at pH 8 for G137V and for
the wild-type, respectively) which indicates a decrease in stability.
Comparison of the melting point with the values previously
reported for other clinically important mutants indicates that
the effect of this mutation is among the most destabilizing
being only marginally higher than the value measured for
G130V (43◦C; Table 1). Interestingly, the two glycine-to-valine
mutations of G130 and G137 lead to similar decreases of the fold
stability.
The G137V Mutant Has No Marked Effect
on In Vitro Iron-Sulfur Cluster Formation
Finally, we probed the effect of the mutation on function by
following enzymatic iron-sulfur cluster formation in vitro in the
presence and absence of wild-type and G137V mutated frataxin.
In the assay, cysteine is converted into alanine and persulfide
by the desulfurase Nfs1/IscS. The persulfide is passed on to the
scaffold protein Isu (or IscU in prokaryotes) where, under strict
anerobic and reducing conditions, the cluster forms as evidenced
by absorbance spectroscopy detected at 400–550 nm (Yang et al.,
2006; Adinolfi et al., 2009). It was previously demonstrated that
frataxin has a marked effect on this in vitro assay which depends
on the origin of the desulfurase (Bridwell-Rabb et al., 2012):
eukaryotic frataxin is an activator of the enzymatic activity of
NFS1 (Tsai and Barondeau, 2010), whereas prokaryotic frataxin
acts as a strong inhibitor of bacterial IscS (Adinolfi et al.,
2009). In vivo, yeast, bacterial and human proteins rescue,
albeit not completely, function in knock-out systems (Cavadini
et al., 2000; Bedekovics et al., 2007). Interestingly, when we
compared the effect of the G130V mutant in the assay with
that of wild-type frataxin, we did not observe any marked
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FIGURE 2 | Multiple alignment of mammalian frataxins compared to the yeast and E. coli orthologs. The position of G137 is marked with a red arrow.
G137 and in general the loop residues are conserved in mammalians but not in other species. The alignment was done using the freely available Clustalx software
(http://www.clustal.org/). Stars stand for completely conserved residues, colons and dots for decreasing conservation.
difference of behavior comparing the effect of wild-type frataxin
and the mutant (Figure 5) suggesting that mutation has no
a direct functional effect atleast under the conditions of this
assay.
FIGURE 3 | Tendency of the G137V mutant to form inclusion bodies in
bacteria. The wild-type and G137V mutant are compared on Nu-PAGE MES
SDS gel. For each fraction (NI, Tot L, Solub, INSOL, FT, W1 and E), the first
sample loaded is wild type and the second is G137V. NI stands for
Non-Induced fractions (before induction with IPTG); Tot L: fractions after
3 h-induction with IPTG, Total Lysate; Solub: Soluble fraction of the previous
Tot L; INSOL: Insoluble fraction corresponding to the inclusion bodies; FT:
Flow Through after first step NI-NTA purification; W1: first Wash; E: Elution
with 300 mM Imidazole. The arrows indicate retention of the G137V mutant in
inclusion bodies explaining the lower final concentration of proteins obtained in
the elution after the first step of purification compared to the wild-type protein.
These results indicate that, while affecting the stability of
the protein, the G137V mutation does not significantly impair
function, that is, when frataxin is folded, its function is not
affected by the mutation.
The G137V Mutation has Devastating
Effects on the Protein Levels
The frataxin levels were estimated by Western blots on the blood
of the proband and compared with those of his parents and of a
healthy control (Figure 6). As expected, the levels of frataxin of
the proband were appreciably lower than those of the control (ca.
50% lower). The levels in the heterozygous father are comparable
to those of the control. Surprisingly, the mother’s levels were also
low and comparable to those of the proband despite the fact that
the mother heterozygote for the point mutation and a normal
allele is not affected by FRDA. However, it is worth mentioning
that the mother had been administered chemiotherapy as a
cancer treatment.
DISCUSSION
Although FRDA is mainly caused by partial impairment of
frataxin expression (Campuzano et al., 1996), 4% of FRDA
patients are heterozygous, presenting a triplet expansion on one
allele and a deleterious point mutation on the other allele. About
20 different point mutations are currently known (Musco et al.,
2000; Correia et al., 2006), some of which accounting for atypical
clinical presentations. Contrary to the common GAA expansion
that alters the levels of protein expression, FRDApointmutations
are usually thought to be associated with a reduced function of
the expressed protein and are thus interesting because they may
help us to establish causal linkages between genetic variations and
biological phenotypes.
Here, we analyzed the effects of a mutation found in a
heterozygote patient carrying a moderate expansion on one allele
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FIGURE 4 | Probing the structure of the G137V mutant and comparison
with the wild-type protein. The spectra of wild-type human frataxin are
plotted in black, those of the mutant in red. (A) Comparison of the
one-dimensional 1H nuclear magnetic resonance (NMR) spectra recorded in
H2O/D2O (90/10 v/v) at pH 8. (B) Far-UV circular dichroism (CD) spectra.
(C) Thermal denaturation scans monitored by far-UV CD. The spectra were
recorded at 220 nm and pH 8. CD intensities are presented as the CD
absorption coefficient calculated on a mean residue weight basis (∆εMRW).
and a point mutation G137V on the other. During the refereeing
process, it was brought to our attention that, interestingly, this
mutation had already been reported independently (Costantini
et al., 2013). The patient’s age at disease onset and progression
are similar to those reported here, supporting a causative
relationship between this mutation and the ataxic phenotype. To
rationalize the effect of the G137V mutation and understand the
mechanism which leads to disease, we analyzed the consequence
TABLE 1 | Comparison of the melting temperatures of the different
frataxin variants.
Variant pH Melting temperature
WT 7.9 66.3
D122Y 7.7 50.4
G130V 7.5 43.2
G137V 8.0 46.0
I154F 8.5 50.7
W155R 9.2 61.4
The values for the variants not described in this work are reported by Correia et al.
(2006).
FIGURE 5 | In vitro enzymatic reconstitution of iron sulfur clusters.
Absorption spectra were recorded as a function of time in the absence of
frataxin and in the presence of wild-type frataxin or the mutants G137V and
W155R. The experiments were carried out using 50 µM IscU, 25 µM iron,
250 µM cysteine, 3 mM DTT and 1 µM Nfs1. When present, the frataxin
concentration was 50 µM. Only the initial rates were monitored and compared
to the control.
of the mutation on protein structure, stability and function
of human frataxin in vitro. The mutant protein is correctly
folded and fully functional in our assays even though when
put into the context of other mutations, G137V seems to have
FIGURE 6 | Western blot results to probe the frataxin levels in the
blood. (A) Total cell extracts were resolved on SDS–PAGE and analyzed with
anti-frataxin antibody, or anti-actin, as a loading control. The graph represents
relative mean frataxin abundance as quantitated by densitometric analysis of
three technical replicates from two different experiments, normalized with actin
levels. Error bars represents standard deviation of the mean.
(B) Representative western blot analysis out of three performed with similar
results, is shown.
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a strong effect on destabilization. We observed a substantial
decrease in the thermodynamic stability of the G137V variant
during thermal unfolding as compared to most of the other
mutations (wild type > W155R > I154F > D122Y > G137 >
G130V), although unfolding is reversible in all cases under the
conditions of the experiment. This result can be rationalized by
considering that in the frataxin 3D structure, G137 is in the
turn between the β2 and β3 strands. It is an exposed residue
conserved in mammalian frataxins. Glycines are important
residues for the unique properties of their energy landscapes
which allow these residues to adopt backbone conformations
also in the disallowed region of the Ramachandran plot. For
this reason, they are often hosted in loops where they have the
important role of providing entropic tension that is essential for
folding (Thomas, 1990). Any substitution will necessarily lead
to destabilization of the protein. On this account, it is easy to
understand the similar destabilizing effect observed for G130V
and G137V. Interestingly, in the 3D structure, Asp122, another
residues involved in a point mutation of clinical importance,
packs against Gly137 suggesting a correlated effect of the two
mutations.
Having carried out both a Western blot analysis and
biophysical studies, we clearly observed an effect on the protein
levels but not on function. In other words, when folded, the
mutated frataxin is fully functional but the lower stability makes
less efficient the protein folding process and/or may enhance
degradation. Accordingly, G137V, like other mutants, tends
to form inclusion bodies when overexpressed in bacteria, a
feature that is not typical of the wild-type protein and that was
proposed to be revealing of an intrinsic tendency to aggregate
(Winkelmann et al., 2010).
This may result in lower than normal concentrations of
frataxin as supported by evidence that the frataxin levels in the
patient described here are below the normal ones. This reduction
in protein levels was also identified in the healthy mother of
the subject suggesting that most of the reduction in frataxin
levels could be due to the G137V mutation and not due to the
GAA expansion, the mutation carried by the father, although
the father’s expansion seems to determine the age of onset.
We thus propose that the mechanism acting in some FRDA
heterozygous patients relies on the consequence of a structural
impairment which we will call ‘‘loss of folding efficiency’’ to be
distinguished from loss/gain of function mechanisms. Although
quite different from other neurodegenerative diseases due to
toxic aggregation, this mechanism may be important in most
of the heterozygous patients and may be relevant also in other
diseases.
These considerations might suggest a possible therapeutic
application for selective treatment of patients having frataxin
mutations with reduced folding stability. It is known that the
function of some thermodynamically unstable mutant proteins
can be recovered in the presence of chemical chaperones (i.e.,
low molecular weight compounds, such as the cellular osmolytes
glycerol and trimethylamine N-oxide), that are able to stabilize
nonspecifically the native conformation of many proteins, or by
the presence of ligands and inhibitors that specifically bind to
a protein, so-called pharmacologic chaperones (Bernier et al.,
2004; Atanasov et al., 2007). In this context, it is also important
to mention that prove-of-principle marketed point-mutation
targeting drugs already exist for other proteins (e.g., Ivacaftor
was developed for specific treatment of cystic fibrosis patients
carrying G551D mutation; Kapoor et al., 2014).
It remains however to explain the condition of the patient
given that, overall, the level of frataxin observed is within that
of healthy carriers and comparable to that of the heterozygous
mother carrying the G137V mutation. Consistently, the severity
of this patient’s status is relatively mild. It should be considered
that compound heterozygous patients generally have lower levels
of frataxin than homozygous for expansion but the precise levels
vary dramatically between tissues (Lazaropoulos et al., 2015).
Start codonmutations lead for instance to low levels of frataxin in
buccal cells but preserve immunoreactive frataxin levels in blood
(Lazaropoulos et al., 2015). Furthermore, peripheral frataxin
levels reflect disease features in FRDA but the interpretation
depends strongly on the specific mutation. Another level of
complexity comes also from the possibility that the personal
history of alcohol and drug abuse of this patient could have
contributed if not to the age of onset, which is in the average,
to the worsening of his symptoms even though the frataxin levels
are not in the pathologic range.
Overall, our study thus contributes to show the complexity
of correlating the frataxin levels to disease severity and the
difficulties of providing a unique prediction of disease onset and
progression in heterozygous FRDA patients.
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